Volume-Based Procurement in Mainland China: Key Trends and Planning Future Strategies
Volume-Based Procurement in Mainland China: Key trends and planning future strategies
Qilu Pharma remains at the top with most
winning bids; MNCs remain less visible
Top 10 companies by VBP winning bids
Hisun Pharma
3
2
Hengrui Medicine
1
3
Hansoh Pharma
2
1
5
4
4
3
4
2
3
1
Huahai Pharma
7
Kelun Pharma
1
5
4
Fosun
2
CSPC
1
3
Yangzi River
2
Sino Biopharm
Qilu Pharma
4
5
4
4
3
4
8
5
7
0
5
10
Round 1
Round 2
Round 3
Round 4
▸ Clarivate™
7
4
8
6
6
6
6
6
15
20
20
25
The VBP has prompted a sharp decline in
prices of generic drugs, which in turn has led
to considerable pricing pressure and
diminishing profit margins for the concerned
companies.
Several MNCs have reported a decline in
revenues for their products included in the
VBP. Some of the companies are doubtful of
their plans for participation in future VBP
programs.
Source: GBI analysis, Clarivate
6View entire presentation